Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections

The approval marks a major milestone in the global fight against antimicrobial resistance

Pfizer’s BRAFTOVI combo doubles progression-free survival in aggressive colorectal cancer trial

The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival

Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial

This marks one of the most closely watched oncology readouts at this year’s medical congress

International scientists say deuterium research could reshape medicine

The conference highlighted research suggesting that deuterium levels may influence key biological processes

Pfizer and FITT IIT Delhi identify 20 health startups under innovation programme

Selected ventures to receive grants and structured intellectual property support to strengthen protection and management of healthcare innovations

Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial

The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer

AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis

FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough

The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term

FDA delays AstraZeneca decision on camizestrant as regulators seek more data

The filing is backed by results from the pivotal SERENA-6 Phase III trial

Fermenta Biotech reports 26% revenue growth in FY26